UK Markets close in 4 hrs 11 mins

Allergy Therapeutics plc (AGYTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.27650.0000 (0.00%)
At close: 01:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.2765
Open0.2765
BidN/A x N/A
AskN/A x N/A
Day's range0.2765 - 0.2765
52-week range0.0019 - 0.5390
Volume300
Avg. volume100
Market cap177.457M
Beta (5Y monthly)1.57
PE ratio (TTM)46.08
EPS (TTM)0.0060
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Interim Results for the six months ended 31 December 2021

    Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two pivotal trials Portfolio focused on high value growth products to enhance future profitabilityGround-breaking Phase I trial of peanut allergy vaccine on track to commence in 2022 following recent FDA clearance of IND application with data expected sooner than previously anticipatedPivotal Phase III trial of short-cou

  • Simply Wall St.

    Allergy Therapeutics' (LON:AGY) investors will be pleased with their decent 79% return over the last three years

    It hasn't been the best quarter for Allergy Therapeutics plc ( LON:AGY ) shareholders, since the share price has fallen...

  • Globe Newswire

    Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut

    Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022Topline data from first-in-human trial expected in H1 2023Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of action of the vaccine candidate 26 January 2022 Allergy Therapeutics